Matches in SemOpenAlex for { <https://semopenalex.org/work/W3004787369> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W3004787369 abstract "491 Background: Evidence supporting second-line therapies has become available for aHCC, including regorafenib, cabozantinib, ramucirumab, and nivolumab. The optimal second-line treatment regimen is unknown, and there remains limited real-world data about the eligibility of patients for second-line therapies in aHCC. We aimed to characterize the real-world eligibility and use of second-line therapies post sorafenib. Methods: We identified all patients with aHCC who received ≥1 cycle of first-line sorafenib between January 1, 2014 and December 31, 2017 across 6 centers in British Columbia (BC), Canada. All patients were required to be Child-Pugh class A for initiation of sorafenib in BC. Baseline characteristics and clinical outcomes were reviewed. Eligibility for second-line therapy was determined using the RESORCE and CELESTIAL study entry criteria. Results: Of 144 patients with advanced HCC who received ≥1 cycle of first-line sorafenib, median age was 65.3 years (range 32.2-83.4) and 85% were male. Median duration of sorafenib was 2.6 months. 12 patients (8%) went on to receive second-line treatment. 37 patients (26%) were deemed eligible for second-line systemic therapy. Primary reasons for ineligibility included ECOG ≥2 (58%), and deterioration to Child-Pugh status B (28%). On Cox regression, improved survival was associated with better ECOG and recurrent disease. (Table). Kaplan-Meier analysis demonstrated that eligibility for second-line treatment was associated with improved median overall survival from end of first-line treatment (8.5 vs. 5.1 months; p<0.01). Conclusions: Only a minority of real-world patients with aHCC were eligible for second-line therapies based on second-line trial criteria. Given the high-rate of attrition, improved first-line treatment options are urgently needed. [Table: see text]" @default.
- W3004787369 created "2020-02-14" @default.
- W3004787369 creator A5001731680 @default.
- W3004787369 creator A5008869204 @default.
- W3004787369 creator A5028653569 @default.
- W3004787369 creator A5070331492 @default.
- W3004787369 creator A5078936080 @default.
- W3004787369 creator A5089913686 @default.
- W3004787369 date "2020-02-01" @default.
- W3004787369 modified "2023-09-25" @default.
- W3004787369 title "Eligibility for second-line therapy in patients with advanced hepatocellular carcinoma (aHCC): A BC Cancer population-based study." @default.
- W3004787369 doi "https://doi.org/10.1200/jco.2020.38.4_suppl.491" @default.
- W3004787369 hasPublicationYear "2020" @default.
- W3004787369 type Work @default.
- W3004787369 sameAs 3004787369 @default.
- W3004787369 citedByCount "1" @default.
- W3004787369 countsByYear W30047873692021 @default.
- W3004787369 crossrefType "journal-article" @default.
- W3004787369 hasAuthorship W3004787369A5001731680 @default.
- W3004787369 hasAuthorship W3004787369A5008869204 @default.
- W3004787369 hasAuthorship W3004787369A5028653569 @default.
- W3004787369 hasAuthorship W3004787369A5070331492 @default.
- W3004787369 hasAuthorship W3004787369A5078936080 @default.
- W3004787369 hasAuthorship W3004787369A5089913686 @default.
- W3004787369 hasConcept C121608353 @default.
- W3004787369 hasConcept C126322002 @default.
- W3004787369 hasConcept C141071460 @default.
- W3004787369 hasConcept C143998085 @default.
- W3004787369 hasConcept C2776248978 @default.
- W3004787369 hasConcept C2778019345 @default.
- W3004787369 hasConcept C2778695046 @default.
- W3004787369 hasConcept C2779551604 @default.
- W3004787369 hasConcept C2781064419 @default.
- W3004787369 hasConcept C2781413609 @default.
- W3004787369 hasConcept C2908647359 @default.
- W3004787369 hasConcept C526805850 @default.
- W3004787369 hasConcept C71924100 @default.
- W3004787369 hasConcept C99454951 @default.
- W3004787369 hasConceptScore W3004787369C121608353 @default.
- W3004787369 hasConceptScore W3004787369C126322002 @default.
- W3004787369 hasConceptScore W3004787369C141071460 @default.
- W3004787369 hasConceptScore W3004787369C143998085 @default.
- W3004787369 hasConceptScore W3004787369C2776248978 @default.
- W3004787369 hasConceptScore W3004787369C2778019345 @default.
- W3004787369 hasConceptScore W3004787369C2778695046 @default.
- W3004787369 hasConceptScore W3004787369C2779551604 @default.
- W3004787369 hasConceptScore W3004787369C2781064419 @default.
- W3004787369 hasConceptScore W3004787369C2781413609 @default.
- W3004787369 hasConceptScore W3004787369C2908647359 @default.
- W3004787369 hasConceptScore W3004787369C526805850 @default.
- W3004787369 hasConceptScore W3004787369C71924100 @default.
- W3004787369 hasConceptScore W3004787369C99454951 @default.
- W3004787369 hasLocation W30047873691 @default.
- W3004787369 hasOpenAccess W3004787369 @default.
- W3004787369 hasPrimaryLocation W30047873691 @default.
- W3004787369 hasRelatedWork W10794003 @default.
- W3004787369 hasRelatedWork W11388833 @default.
- W3004787369 hasRelatedWork W13885862 @default.
- W3004787369 hasRelatedWork W14186601 @default.
- W3004787369 hasRelatedWork W14450087 @default.
- W3004787369 hasRelatedWork W18224072 @default.
- W3004787369 hasRelatedWork W18648799 @default.
- W3004787369 hasRelatedWork W4310718 @default.
- W3004787369 hasRelatedWork W9288866 @default.
- W3004787369 hasRelatedWork W6840905 @default.
- W3004787369 isParatext "false" @default.
- W3004787369 isRetracted "false" @default.
- W3004787369 magId "3004787369" @default.
- W3004787369 workType "article" @default.